Latest news
Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M - BioPharma DiveBioPharma Dive · Thu, 06 Aug 2026 19:14:51 GMTVertex Pharmaceuticals Ups 2026 Outlook Amid Heavy Investment - The Globe and MailThe Globe and Mail · Thu, 06 Aug 2026 00:34:00 GMTLatigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx - Fierce BiotechFierce Biotech · Tue, 04 Aug 2026 11:55:09 GMTVertex Pharmaceuticals’ Q2 Earnings Call Confirmed an $8.8 Billion Bet. Here’s What That Means for the Stock - TIKR.comTIKR.com · Tue, 04 Aug 2026 10:20:13 GMTNew Non-Opioid Pain Relief Company Latigo (LTGO.US) Plans IPO to Raise Up to $288 Million, Nav1.8 Inhibitor Targets Vertex Pharmaceuticals (VRTX.US) Billion-Dollar Market - BitgetBitget · Tue, 04 Aug 2026 01:16:11 GMTVertex Pharmaceuticals Bumps Up Fiscal Year Outlook on Growth of Cystic Fibrosis Drugs - marketscreener.commarketscreener.com · Mon, 03 Aug 2026 21:01:28 GMTVertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations - TradingViewTradingView · Mon, 03 Aug 2026 20:36:47 GMTVertex Pharmaceuticals (VRTX) Releases Q2 2026 Earnings: Revenue Up 12.45% - Quiver QuantitativeQuiver Quantitative · Mon, 03 Aug 2026 20:36:00 GMT